---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-128212"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:26:49.467138+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion closes $150M term loan and $210M convertible debt exchange to refinance 2025 notes

## Summary
- Entered $150M senior secured term loan at 9.75% cash / 11.75% PIK, due Dec 2029, with minimum liquidity covenant of $50M.
- Exchanged ~$210.1M of 4% 2025 notes for $57.5M in new 5.75% notes due 2030 and $153.4M cash; ~$42.5M raised via subscription for new notes.
- New notes due 2030 have a conversion rate of 326.7974 shares/$1,000 (approx $3.06/share) and are redeemable from Dec 2027 at 130% threshold.
- Proceeds from term loan and subscription will fund cash portion of exchange and general corporate purposes.
- After closing, ~$54.9M of 2025 notes remain outstanding with unchanged terms.

## SEC filing metadata
- accession: 0001104659-24-128212
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465924128212/0001104659-24-128212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465924128212/tm2430949d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-128212
- JSON: https://secwatch.observer/filing/0001104659-24-128212.json
- Plain text: https://secwatch.observer/filing/0001104659-24-128212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.